Prevalence and Prognosis of Cardiac Amiloidosis in Turkey

Last updated: May 31, 2021
Sponsor: Turkish Society of Cardiology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Amyloidosis

Treatment

N/A

Clinical Study ID

NCT04915235
PAPCAT
  • Ages > 18
  • All Genders

Study Summary

Patients with left ventricular hypertrophy are further examined according to an algorithm to check if they have a cardiac amyloidosis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with left ventricular hypertrophy without left ventricular pressure or volume (IVS≥13mm)
  • Patients with left ventricular hypertrophy and hypertension or aortic stenosis withoutleft ventricular pressure or volume (IVS>15mm)

Exclusion

Exclusion Criteria:

  • Patients with left ventricular pressure or volume except the ones with aortic stenosisand arterial hypertension
  • Patients with sigmoid septum and their hypertrophy limited in sigmoid area
  • Patients with highly probable sarcometric hypertrophy cardiomyopathy confirmed with LVmorhpology and genetic testing

Study Design

Total Participants: 2087
Study Start date:
September 18, 2020
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Dokuz Eylul University Faculty of Medicine

    Izmir,
    Turkey

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.